Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
NAICS : 325412
ISIN : CNE100000924
Share Class Description:
STU:2TZ: Class SCompare
Compare
Traded in other countries / regions
600329.ChinaT14.Singapore2TZ.Germany IPO Date
2013-04-09Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.13 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | 1.17 | |||||
| Interest Coverage | 23.82 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.6 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.5 | |||||
| 3-Year EBITDA Growth Rate | 12.7 | |||||
| 3-Year EPS without NRI Growth Rate | 14.5 | |||||
| 3-Year FCF Growth Rate | 4.2 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.75 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.05 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.88 | |||||
| 9-Day RSI | 45.32 | |||||
| 14-Day RSI | 47.53 | |||||
| 3-1 Month Momentum % | -5.26 | |||||
| 6-1 Month Momentum % | 5.85 | |||||
| 12-1 Month Momentum % | 13.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | |||||
| Quick Ratio | 1.31 | |||||
| Cash Ratio | 0.35 | |||||
| Days Inventory | 135.13 | |||||
| Days Sales Outstanding | 111.93 | |||||
| Days Payable | 90.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 8.15 | |||||
| Dividend Payout Ratio | 0.96 | |||||
| 3-Year Dividend Growth Rate | 55.1 | |||||
| Forward Dividend Yield % | 8.15 | |||||
| 5-Year Yield-on-Cost % | 39.62 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 3.2 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.85 | |||||
| Operating Margin % | 11.15 | |||||
| Net Margin % | 11.6 | |||||
| FCF Margin % | 12.94 | |||||
| ROE % | 14.24 | |||||
| ROA % | 8.56 | |||||
| ROIC % | 14.3 | |||||
| 3-Year ROIIC % | 32.03 | |||||
| ROC (Joel Greenblatt) % | 43.76 | |||||
| ROCE % | 15.79 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.79 | |||||
| Forward PE Ratio | 7.98 | |||||
| PE Ratio without NRI | 22.53 | |||||
| Shiller PE Ratio | 32.61 | |||||
| Price-to-Owner-Earnings | 28.95 | |||||
| PEG Ratio | 2.11 | |||||
| PS Ratio | 2.87 | |||||
| PB Ratio | 3.6 | |||||
| Price-to-Tangible-Book | 3.84 | |||||
| Price-to-Free-Cash-Flow | 22.2 | |||||
| Price-to-Operating-Cash-Flow | 19.6 | |||||
| EV-to-EBIT | 18.3 | |||||
| EV-to-EBITDA | 18.3 | |||||
| EV-to-Revenue | 2.49 | |||||
| EV-to-FCF | 19.31 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Projected-FCF | 2.22 | |||||
| Price-to-Median-PS-Value | 1.3 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.99 | |||||
| Price-to-Graham-Number | 1.96 | |||||
| Price-to-Net-Current-Asset-Value | 9.07 | |||||
| Earnings Yield (Greenblatt) % | 5.46 | |||||
| FCF Yield % | 5.14 | |||||
| Forward Rate of Return (Yacktman) % | 13.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,028.67 | ||
| EPS (TTM) (€) | 0.155 | ||
| Beta | 0.09 | ||
| 3-Year Sharpe Ratio | 0.8 | ||
| 3-Year Sortino Ratio | 1.97 | ||
| Volatility % | 28.25 | ||
| 14-Day RSI | 47.53 | ||
| 14-Day ATR (€) | 0.016289 | ||
| 20-Day SMA (€) | 2.01226 | ||
| 12-1 Month Momentum % | 13.86 | ||
| 52-Week Range (€) | 1.7216 - 2.3925 | ||
| Shares Outstanding (Mil) | 770.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Frequently Asked Questions
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ)'s stock price today?
The current price of STU:2TZ is €1.99. The 52 week high of STU:2TZ is €2.39 and 52 week low is €1.72.
When is next earnings date of Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ)?
The next earnings date of Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ) is .
Does Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ) pay dividends? If so, how much?
The Dividend Yield %  of Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ) is 8.15% (As of Today), Highest Dividend Payout Ratio of Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ) was 0.96. The lowest was 0.11. And the median was 0.32. The  Forward Dividend Yield % of Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd(STU:2TZ) is 8.15%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers